Press release: Sequana Medical Announces US FDA Approval of - GlobeNewswire
Sequana Medical announces US FDA approval of alfapump® for treating recurrent or refractory ascites due to liver cirrhosis, marking it the first active implantable medical device in the US for this purpose. The device automatically removes ascites into the bladder, with over 1,000 systems implanted. The US market opportunity is estimated at over $2 billion in 2025, with a planned commercial launch in H2 2025.
Highlighted Terms
Related News
Sequana Medical announces US FDA approval of alfapump® for treating recurrent or refractory ascites due to liver cirrhosis, marking it the first active implantable medical device in the US for this purpose. The device automatically removes ascites into the bladder, with over 1,000 systems implanted. The US market opportunity is estimated at over $2 billion in 2025, with a planned commercial launch in H2 2025.